Aptima® BV and CV/TV Assay

The #1 reason your patient comes in

Approximately 10M women visit the OB/GYN each year for a vaginitis infection. Our test detects the three most common causes of infectious vaginitis–bacterial vaginosis, candida vaginitis and trichomoniasis—that make up to 95% of these cases.1,2,3

While yeast infection or candida vaginitis (CV) is usually a result of overgrowth of candida albicans, it can also be caused by the azole-resistant strain candida glabrata, which requires a different treatment pathway than C. albicans. “Trich” (TV), the most common curable STI, can contribute to more serious health outcomes if left untreated.4,5


Clear the confusion
around co-infection

  • Pathogen coinfection can occur frequently in women with vaginitis. Approximately 20–30%
    of women with bacterial vaginosis (BV) are coinfected with candida species. Coexistence of BV pathogens and T. vaginalis is even more common, with co-infection rates of 60–80%.6
  • Most conventional methods of diagnosis to detect positive culture—including wet mount, microscopy, or laboratory examination—lack accuracy and are also not easily available.7
  • In contrast, NAAT molecular tests are highly sensitive, detecting more co-infection cases than clinical diagnosis with wet mount, culture, and Amsel’s criteria.8

Pinpoint the problem with ultra-sensitive molecular testing8

Accurate diagnosis using the Aptima® Bacterial Vaginosis and Aptima® Candida/Trichomonas Vaginitis Assays provide objective tools for the clinician to accurately diagnose and treat patients.8

The Aptima® BV and CV/TV tests detect and qualitatively report results for the following organisms:9,10

  • Candida species group (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis)
  • Candida glabrata
  • Lactobacillus, Gardnerella vaginalis, Atopobium vaginae
  • Trichomonas vaginalis

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?

1. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol. 1991;165(Part 2): 1168-76. 2. American College of Obstetricians and Gynecologists. Vaginitis. Published August 2011. Accessed September 2, 2020. https://www.acog.org/Patients/FAQs/Vaginitis. 3. Paladine HL. Vaginitis: Diagnosis and Treatment. Am Fam Physician. 2018 Mar 1;97(5):321-329. 4. Thomason J, et al. Trichomonas vaginalis. Obst Gynecol. 1989;74(3)2:536-541. 5. CDC. Sexually Transmitted Diseases Treatment Guidelines, 2015. Published June 5, 2015. Accessed September 2, 2020. http://www.cdc.gov/std/tg2015/tg-2015-print.pdf. 6. Sobel, J.D., Subramanian, C., Foxman, B. et al. Mixed Vaginitis—More Than Coinfection and With Therapeutic Implications. Curr. Infect Dis Rep 15, 104–108 (2013). https://doi.org/10.1007/s11908-013-0325-5. 7. Nye M, et al. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200(2):188.e1-7. 8. Schwebke JR, et al. Diagnostic Performance of a Molecular Test Versus Clinician Assessment of Vaginitis. J Clin Microbiol. 2018; 56. doi:10.1128/JCM.00252-18. 9. Aptima BV Assay Package Insert. AW-18811 Rev. 001. San Diego, CA: Hologic, Inc, 2019 10. Aptima CV/TV Assay Package Insert. AW-18812 Rev. 001. San Diego, CA: Hologic, Inc, 2019